

Emboline’s “enabling TAVI” aortic embolic protection technology is selected for presentation at TCT 2016

The *Emboliner*™ embolic protection catheter is a new approach to reducing aortic embolic risks, providing *Total Embolic Protection* from procedural-related emboli

To be presented in the symposium, “Interventional Innovation I: Interventional Innovation and Best Technological Concepts I,” in “Session IV. TAVR Innovations and Ancillary Devices,” on Sunday, October 30th, at 11:18 am, Room 209, Level 2, Walter E. Washington Convention Center, Washington, DC

SANTA CRUZ, Calif., October 28, 2016—**Emboline, Inc.**, an emerging medical device company, announced today that its *Emboliner*™ technology will be featured at “TCT2016,” the United States’ most important interventional cardiology-focused annual scientific meeting of the year, on Sunday, October 30th, in Washington, DC.

The Company is focused on developing its novel *Emboliner*™ embolic protection catheter: a game-changing, next-generation system intended to provide complete protection of the arterial bed (both the cerebrals and the aortic lumen) utilizing a uniquely ported design that maintains tool access through the filter, while minimizing procedural disruption with no need for an additional procedural access.

“Given the tremendous amount of attention among cardiologists being given to TAVI (transcatheter aortic valve implantation), our emergence is especially timely,” said **Scott Russell**, Emboline’s President & CEO. “For these exciting new TAVR procedures to reach their true potential, the embolic risks must be properly managed. Our *Emboliner*™ embolic protection catheter not only reduces the risk of embolic events from these procedures, but also offers protection for the rest of the body without requiring an additional procedural access site or the need for significantly more procedural time. Certainly, the visibility for our technology among interventional cardiologists at the most important cardiovascular meeting in the United States this year is an important landmark in our development of a game-changing device for the aortic embolic-protection space.”

The Company’s technologies are derived from intellectual property invented by Amir Belson, MD. Dr. Belson previously founded **NeoGuide Systems**, a company that developed a platform technology for minimally invasive surgical procedures and was acquired by **Intuitive Surgical** in 2009; as well as **Vascular Pathways**, which developed a “can’t miss” IV catheter that was chosen as one of the 10 best inventions of 2009 by Popular Science magazine, and was subsequently acquired by C.R. Bard in 2015. More recently, Dr. Belson also has founded **ZipLine Medical**, **Qool Therapeutics**, **Radiation Medical**, **Vasostitch**, and **Modular Surgical**.

CLINICAL NEED

Cerebral embolism is a known complication of cardiac surgery, cardiopulmonary bypass and catheter-based interventional cardiology and electrophysiology procedures. Embolic particles, which may include thrombus, valve tissue, and calcification, may become dislodged by surgical or catheter manipulations and enter the bloodstream. Entrapment and removal of these embolic debris would benefit patients and improve the outcome of these procedures. These risks are especially critical in transcatheter aortic valve replacement (TAVR), where about 75% of patients develop new ischemic brain lesions following the procedure. First-generation embolic protection technologies have been shown to reduce such lesions with a corresponding improvement in neurological and neurocognitive outcomes. The *Emboliner*™ offers significant advantages over first-generation technologies in terms of both reliability and comprehensiveness of embolic containment, as well as ease of use.

For further information about Emboline’s technologies, please contact Emboline’s CEO **Scott Russell** at rsussell@emboline.com, 408/416-2450, x102.